Statera Biopharma has announced its intent to enter into a non-binding term sheet with regard to a strategic partnership with Lay Sciences, a development and commercialisation company of innovative solutions to license global manufacturing rights to some of Lay Sciences’ IgY products featuring avian antibodies as an active ingredient.
16 May 2022
15 Dec 2021
Zealand Pharma has announced a financing agreement with Oberland Capital Management that includes an upfront payment of $100m in exchange for a seven-year, interest-only secured note.
01 Dec 2021
AbbVie has sought approval from the European Medicines Agency (EMA) for risankizumab (Skyrizi, 600 mg intravenous (IV) induction and 360 mg subcutaneous (SC) maintenance therapy), to treat patients who are 16 years and above suffering with moderate to severe active Crohn's disease.